Scarica l'app Stockscreener
1.05
1.94%
0.02
Dopo l'orario di chiusura:
1.02
-0.03
-2.86%
Precedente Chiudi:
$1.03
Aprire:
$1.06
Volume 24 ore:
89,129
Relative Volume:
0.05
Capitalizzazione di mercato:
$5.75M
Reddito:
-
Utile/perdita netta:
$-8.72M
Rapporto P/E:
-0.1914
EPS:
-5.4871
Flusso di cassa netto:
$-5.47M
1 W Prestazione:
-6.25%
1M Prestazione:
-8.70%
6M Prestazione:
-34.78%
1 anno Prestazione:
-62.70%
Intervallo 1D:
$1.02
$1.07
Intervallo di 1 settimana:
$1.015
$1.21
Portata 52W:
$0.7449
$3.61
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Nome
Galmed Pharmaceuticals Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta GLMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.05 | 5.64M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-05-22 | Downgrade | B. Riley FBR | Buy → Neutral |
| 2020-02-04 | Iniziato | Craig Hallum | Buy |
| 2020-01-30 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-12-02 | Iniziato | Canaccord Genuity | Buy |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-08-02 | Reiterato | Maxim Group | Buy |
| 2018-07-13 | Iniziato | Stifel | Buy |
| 2018-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-06-12 | Reiterato | H.C. Wainwright | Buy |
| 2018-03-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2018-02-14 | Downgrade | Maxim Group | Buy → Hold |
| 2018-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-15 | Iniziato | ROTH Capital | Buy |
| 2017-08-08 | Reiterato | H.C. Wainwright | Buy |
| 2017-07-31 | Reiterato | Maxim Group | Buy |
| 2016-08-01 | Reiterato | Maxim Group | Buy |
| 2016-07-06 | Ripresa | ROTH Capital | Buy |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2015-05-06 | Iniziato | Sun Trust Rbsn Humphrey | Buy |
Mostra tutto
Galmed Pharmaceuticals Ltd Borsa (GLMD) Ultime notizie
Galmed to present data on Aramchol’s potential in liver cancer - Investing.com
Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks
Galmed to present data on Aramchol’s potential in liver cancer By Investing.com - Investing.com Australia
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - Yahoo Finance
Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Nigeria
Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Watchlists - Newser
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Galmed stock rises after patent grant for MASH combo therapy By Investing.com - Investing.com Nigeria
Galmed stock rises after patent grant for MASH combo therapy - Investing.com
Galmed receives patent for combination therapy in South Korea - Investing.com
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - WV News
Can Galmed Pharmaceuticals Ltd. (GPH) stock sustain free cash flowQuarterly Trade Review & Accurate Trade Setup Notifications - Newser
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Is Galmed Pharmaceuticals Ltd. (GPH) stock supported by strong fundamentals2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investing - Newser
Can Galmed Pharmaceuticals Ltd. (GPH) stock attract ESG investmentsTrade Volume Summary & High Accuracy Investment Signals - Newser
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - MSN
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth era2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser
Galmed reports $19.2 million cash position, advances Aramchol programs By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com
Galmed reports $19.2 million cash position, advances Aramchol programs - Investing.com
Galmed Issues CEO Letter to Shareholders - Sahm
Galmed Pharmaceuticals (GLMD) Stock Analysis Report | Financials & Insights - Benzinga
What drives Galmed Pharmaceuticals Ltd stock priceEx-Dividend Date Alerts & Fast Growing Portfolio Trading - earlytimes.in
Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Quarterly Trade Report & Consistent Profit Trading Strategies - BỘ NỘI VỤ
Energy Moves: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - moha.gov.vn
EV Market: How Galmed Pharmaceuticals Ltd. stock compares to growth peersJuly 2025 Action & Fast Gaining Stock Reports - BỘ NỘI VỤ
Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Galmed Pharmaceuticals: Q3 Earnings Snapshot - Stamford Advocate
How Galmed Pharmaceuticals Ltd. stock compares to growth peersJuly 2025 Fed Impact & Capital Protection Trade Alerts - BỘ NỘI VỤ
Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs - TipRanks
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025July 2025 Opening Moves & AI Forecast for Swing Trade Picks - BỘ NỘI VỤ
MSN Money - MSN
Galmed Pharmaceuticals Ltd. (GLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Key metrics from Galmed Pharmaceuticals Ltd.’s quarterly dataJuly 2025 Sector Moves & Verified Stock Trade Ideas - newser.com
Can swing trading help recover from Galmed Pharmaceuticals Ltd. lossesTrade Ideas & Daily Profit Maximizing Tips - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock resilient in recession scenarios - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock suitable for passive index fundsWeekly Trading Summary & Verified Momentum Watchlists - newser.com
Why Galmed Pharmaceuticals Ltd. stock attracts global investorsWeekly Gains Summary & Detailed Earnings Play Strategies - newser.com
Galmed Pharmaceuticals Ltd Azioni (GLMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):